| [1] |
WU NJ, LIU TT, TIAN MM, et al. Albumin, an interesting and functionally diverse protein, varies from‘native’ to‘effective’(Review)[J]. Mol Med Rep, 2024, 29( 2): 24. DOI: 10.3892/mmr.2023.13147. |
| [2] |
TUFONI M, BALDASSARRE M, ZACCHERINI G, et al. Hemodynamic and systemic effects of albumin in patients with advanced liver disease[J]. Curr Hepatol Rep, 2020, 19( 3): 147- 158. DOI: 10.1007/s11901-020-00521-1. |
| [3] |
COLOMBO G, CLERICI M, GIUSTARINI D, et al. Redox albuminomics: Oxidized albumin in human diseases[J]. Antioxid Redox Signal, 2012, 17( 11): 1515- 1527. DOI: 10.1089/ars.2012.4702. |
| [4] |
ALCARAZ-QUILES J, CASULLERAS M, OETTL K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through P38 mitogen-activated protein kinase: Role in systemic inflammation in decompensated cirrhosis[J]. Hepatology, 2018, 68( 5): 1937- 1952. DOI: 10.1002/hep.30135. |
| [5] |
TAVERNA M, MARIE AL, MIRA JP, et al. Specific antioxidant properties of human serum albumin[J]. Ann Intensive Care, 2013, 3( 1): 4. DOI: 10.1186/2110-5820-3-4. |
| [6] |
TORRES LN, CHUNG KK, SALGADO CL, et al. Low-volume resuscitation with normal saline is associated with microvascular endothelial dysfunction after hemorrhage in rats, compared to colloids and balanced crystalloids[J]. Crit Care, 2017, 21( 1): 160. DOI: 10.1186/s13054-017-1745-7. |
| [7] |
CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7. |
| [8] |
POMPILI E, ZACCHERINI G, PIANO S, et al. Real-world experience with long-term albumin in patients with cirrhosis and ascites[J]. JHEP Rep, 2024, 6( 12): 101221. DOI: 10.1016/j.jhepr.2024.101221. |
| [9] |
CHRIS RUNKEN M, CARACENI P, FERNANDEZ J, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain[J]. Health Econ Rev, 2019, 9( 1): 22. DOI: 10.1186/s13561-019-0237-7. |
| [10] |
CARACENI P, PAVESI M, BALDASSARRE M, et al. The use of human albumin in patients with cirrhosis: A European survey[J]. Expert Rev Gastroenterol Hepatol, 2018, 12( 6): 625- 632. DOI: 10.1080/17474124.2018.1460203. |
| [11] |
CARACENI P, ANGELI P, PRATI D, et al. AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: A 2020 update[J]. Blood Transfus, 2021, 19( 1): 9- 13. DOI: 10.2450/2020.0414-20. |
| [12] |
BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69( 6): 1127- 1138. DOI: 10.1136/gutjnl-2019-318843. |
| [13] |
DOMENICALI M, BALDASSARRE M, GIANNONE FA, et al. Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis[J]. Hepatology, 2014, 60( 6): 1851- 1860. DOI: 10.1002/hep.27322. |
| [14] |
BALDASSARRE M, NALDI M, ZACCHERINI G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications[J]. Hepatology, 2021, 74( 4): 2058- 2073. DOI: 10.1002/hep.31798. |
| [15] |
CASTRO-NARRO G, MOCTEZUMA-VELÁZQUEZ C, MALE-VELÁZQUEZ R, et al. Position statement on the use of albumin in liver cirrhosis[J]. Ann Hepatol, 2022, 27( 4): 100708. DOI: 10.1016/j.aohep.2022.100708. |
| [16] |
POMPILI E, BALDASSARRE M, IANNONE G, et al. Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial[J]. Liver Int, 2024, 44( 9): 2108- 2113. DOI: 10.1111/liv.16020. |
| [17] |
ZACCHERINI G, BALDASSARRE M, TUFONI M, et al. Correction and prevention of hyponatremia in patients with cirrhosis and ascites: Post hoc analysis of the ANSWER study database[J]. Am J Gastroenterol, 2023, 118( 1): 168- 173. DOI: 10.14309/ajg.0000000000001995. |
| [18] |
FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18( 4): 963- 973. e 14. DOI: 10.1016/j.cgh.2019.07.055. |
| [19] |
NALDI M, BALDASSARRE M, DOMENICALI M, et al. Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis[J]. J Pharm Biomed Anal, 2016, 122: 141- 147. DOI: 10.1016/j.jpba.2016.01.048. |
| [20] |
DAS S, MARAS JS, HUSSAIN MS, et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis[J]. Hepatology, 2017, 65( 2): 631- 646. DOI: 10.1002/hep.28897. |
| [21] |
JING WH, JIANG MY, FU XX, et al. Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment[J]. Int J Biol Macromol, 2022, 214: 697- 707. DOI: 10.1016/j.ijbiomac.2022.06.167. |
| [22] |
JALAN R, BERNARDI M. Effective albumin concentration and cirrhosis mortality: From concept to reality[J]. J Hepatol, 2013, 59( 5): 918- 920. DOI: 10.1016/j.jhep.2013.08.001. |
| [23] |
KAZMIERCZAK SC, GURACHEVSKY A, MATTHES G, et al. Electron spin resonance spectroscopy of serum albumin: A novel new test for cancer diagnosis and monitoring[J]. Clin Chem, 2006, 52( 11): 2129- 2134. DOI: 10.1373/clinchem.2006.073148. |
| [24] |
WATANABE H, IMAFUKU T, OTAGIRI M, et al. Clinical implications associated with the posttranslational modification-induced functional impairment of albumin in oxidative stress-related diseases[J]. J Pharm Sci, 2017, 106( 9): 2195- 2203. DOI: 10.1016/j.xphs.2017.03.002. |
| [25] |
CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64( 4): 1249- 1264. DOI: 10.1002/hep.28740. |
| [26] |
XIAO LL, ZHANG F, ZHAO YL, et al. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury[J]. Sci Rep, 2020, 10( 1): 18128. DOI: 10.1038/s41598-020-75141-2. |
| [27] |
LAKIS R, SAUVAGE FL, PINAULT E, et al. Semi-synthetic human albumin isoforms: Production, structure, binding capacities and influence on a routine laboratory test[J]. Int J Biol Macromol, 2023, 250: 126239. DOI: 10.1016/j.ijbiomac.2023.126239. |
| [28] |
RAHALI MA, LAKIS R, SAUVAGE FL, et al. Posttranslational-modifications of human-serum-albumin analysis by a top-down approach validated by a comprehensive bottom-up analysis[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2023, 1224: 123740. DOI: 10.1016/j.jchromb.2023.123740. |
| [29] |
CHEN CY, TSAI WL, LIN PJ, et al. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease[J]. Clin Chem Lab Med, 2011, 49( 11): 1817- 1821. DOI: 10.1515/CCLM.2011.675. |
| [30] |
GIANNONE FA, DOMENICALI M, BALDASSARRE M, et al. Ischaemia-modified albumin: A marker of bacterial infection in hospitalized patients with cirrhosis[J]. Liver Int, 2015, 35( 11): 2425- 2432. DOI: 10.1111/liv.12860. |
| [31] |
SUN LJ, WANG Q, LIU MX, et al. Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease[J]. Endocrine, 2020, 69( 2): 294- 302. DOI: 10.1007/s12020-020-02319-z. |
| [32] |
TADA S, YASUKAWA K, YATOMI Y, et al. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin[J]. Pract Lab Med, 2022, 31: e00281. DOI: 10.1016/j.plabm.2022.e00281. |
DownLoad: